Mendes Marisa I S, Colaço Henrique G, Smith Desirée E C, Ramos Rúben J J F, Pop Ana, van Dooren Silvy J M, Tavares de Almeida Isabel, Kluijtmans Leo A J, Janssen Mirian C H, Rivera Isabel, Salomons Gajja S, Leandro Paula, Blom Henk J
Metabolism and Genetics Group, Research Institute for Medicines and Pharmaceutical Sciences, Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal.
J Inherit Metab Dis. 2014 Mar;37(2):245-54. doi: 10.1007/s10545-013-9647-6. Epub 2013 Aug 23.
A reduced response of cystathionine beta-synthase (CBS) to its allosteric activator S-adenosylmethionine (SAM) has been reported to be a cause of CBS dysfunction in homocystinuria patients. In this work we performed a retrospective analysis of fibroblast data from 62 homocystinuria patients and found that 13 of them presented a disturbed SAM activation. Their genotypic background was identified and the corresponding CBS mutant proteins were produced in E. coli. Nine distinct mutations were detected in 22 independent alleles: the novel mutations p.K269del, p.P427L, p.S500L and p.L540Q; and the previously described mutations p.P49L, p.C165Rfs*2, p.I278T, p.R336H and p.D444N. Expression levels and residual enzyme activities, determined in the soluble fraction of E. coli lysates, strongly correlated with the localization of the affected amino acid residue. C-terminal mutations lead to activities in the range of the wild-type CBS and to oligomeric forms migrating faster than tetramers, suggesting an abnormal conformation that might be responsible for the lack of SAM activation. Mutations in the catalytic core were associated with low protein expression levels, decreased enzyme activities and a higher content of high molecular mass forms. Furthermore, the absence of SAM activation found in the patients' fibroblasts was confirmed for all but one of the characterized recombinant proteins (p.P49L). Our study experimentally supports a deficient regulation of CBS by SAM as a frequently found mechanism in CBS deficiency, which should be considered not only as a valuable diagnostic tool but also as a potential target for the development of new therapeutic approaches in classical homocystinuria.
据报道,胱硫醚β-合酶(CBS)对其变构激活剂S-腺苷甲硫氨酸(SAM)的反应降低是同型胱氨酸尿症患者CBS功能障碍的一个原因。在这项工作中,我们对62名同型胱氨酸尿症患者的成纤维细胞数据进行了回顾性分析,发现其中13人存在SAM激活障碍。确定了他们的基因型背景,并在大肠杆菌中产生了相应的CBS突变蛋白。在22个独立等位基因中检测到9种不同的突变:新突变p.K269del、p.P427L、p.S500L和p.L540Q;以及先前描述的突变p.P49L、p.C165Rfs*2、p.I278T、p.R336H和p.D444N。在大肠杆菌裂解物的可溶部分中测定的表达水平和残余酶活性与受影响氨基酸残基的定位密切相关。C末端突变导致活性在野生型CBS范围内,并导致寡聚体形式的迁移速度快于四聚体,这表明异常构象可能是缺乏SAM激活的原因。催化核心中的突变与低蛋白表达水平、酶活性降低和高分子量形式的含量增加有关。此外,除了一种特征性重组蛋白(p.P49L)外,所有患者成纤维细胞中发现的SAM激活缺失在实验中得到了证实。我们的研究通过实验支持了SAM对CBS的调节缺陷是CBS缺乏中常见的机制,这不仅应被视为一种有价值的诊断工具,而且应被视为经典同型胱氨酸尿症新治疗方法开发的潜在靶点。